Gilead's HIV prevention treatment found 100% effective in late-stage trial
By Eleanor Laise
Company reports first Phase 3 HIV prevention trial ever to show zero infections
Gilead Sciences Inc.'s stock (GILD) jumped 4.5% early Thursday after the company said its experimental twice-yearly injection for HIV prevention was found 100% effective in a late-stage trial.
The injection, lenacapavir, proved superior to Gilead's once-daily oral treatment Truvada in preventing HIV in cisgender women, the company said. The study is the first phase 3 HIV-prevention trial ever to show zero infections, according to Gilead.
Based on the results, an independent data monitoring committee recommended that Gilead offer lenacapavir to all trial participants, halting the blinded phase of the study, the company said.
Previous trials have found challenges with patients adhering to daily pills for HIV PrEP, or pre-exposure prophylaxis, underscoring the potential significance of a twice-yearly option.
If approved, lenacapavir "could provide a critical new choice for HIV prevention that fits into the lives of many people who could benefit from PrEP around the world - especially cisgender women," Linda-Gail Bekker, director of the Desmond Tutu HIV Center at the University of Cape Town, South Africa, said in a statement. The twice-yearly injection "could help address the stigma and discrimination some people may face when taking or storing oral PrEP pills," while also increasing adherence, Bekker said.
Gilead is also studying lenacapavir for HIV PrEP in cisgender men who have sex with men, transgender men, transgender women, and other groups, with results expected later this year or early next year.
Gilead's stock is down 18% this year to date, while the S&P 500 SPX has gained 15.2%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
06-20-24 0945ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks